This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.
Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney
7 ways the EMPA-KIDNEY trial will impact clinical care in CKD
— Daniel Schwartz (@drdschwartzmd) November 27, 2022
A Thread 🧵
Sources @NEJM @NephJC @DiabetesCanada @AmDiabetesAssn @goKDIGO @ESC_Journals @hswapnil @kidney_boy
